New government drug repurposing programs: Opportunities and uncertainties

Johnathan Liddicoat*, Ashleigh Hamidzadeh , Kathleen Liddell, Marco Schito, David Simon, Mateo Aboy, Timo Minssen

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

2 Citations (Scopus)

Abstract

Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, par-tially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europehave created seven drug development programs that aim to overcome these challenges using a variety ofdifferent strategies
Original languageEnglish
Article numbereadl0998
JournalScience Translational Medicine
Volume16
Issue number753
Number of pages4
ISSN1946-6234
DOIs
Publication statusPublished - 2024

Bibliographical note

Liddicoat J, Hamidzadeh A, Liddell K, Schito M, Simon D, Aboy M, Minssen T. New government drug repurposing programs: Opportunities and uncertainties. Sci Transl Med. 2024 Jun 26;16(753):eadl0998. doi: 10.1126/scitranslmed.adl0998. Epub 2024 Jun 26. PMID: 38924430.

Keywords

  • Faculty of Law
  • Government Programs
  • drug R&D
  • new uses
  • drug repurposing
  • Public private partnership
  • Emperical legal studies

Cite this